Tiziana Life Sciences begins dosing last patient in Phase 2 trial of intranasal foralumab for Alzheimer's; topline data expected Q1 2027

Tiziana Life Sciences has begun dosing the last patient in its Phase 2 clinical trial evaluating intranasal foralumab in patients with early/mild Alzheimer's disease. Topline data are anticipated in Q1 2027.

Detected & updated continuously · Source: Nebula